Savara (NASDAQ:SVRA) Stock Price Down 5.4% - What's Next?

Key Points

• Savara shares fell 5.4% to approximately $5.40 in midday trading, with volume down 84% from the stock’s average daily volume.
• Analyst sentiment remains mixed but leans positive: the consensus rating is “Moderate Buy” with a $10.14 price target, despite one sell rating and a recent quarterly earnings miss.
• Savara reported a quarterly loss of $0.16 per share versus the expected $0.14 loss, while institutional investors own 87.93% of the company. Its lead drug candidate, Molgradex, is under regulatory review for a rare lung disease.

Shares of Savara Inc. (NASDAQ:SVRA - Get Free Report) traded down 5.4% on Thursday . The stock traded as low as $5.37 and last traded at $5.3950. 264,368 shares were traded during mid-day trading, a decline of 84% from the average daily volume of 1,609,659 shares. The stock had previously closed at $5.70.

Wall Street Analyst Weigh In

Several brokerages have recently commented on SVRA. Oppenheimer began coverage on Savara in a research note on Friday, April 24th. They set an "outperform" rating and a $11.00 price target on the stock. Weiss Ratings reiterated a "sell (d-)" rating on shares of Savara in a report on Friday, July 17th. Finally, Wall Street Zen upgraded shares of Savara from a "sell" rating to a "hold" rating in a report on Saturday, June 13th. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $10.14.

Savara Stock Performance

The company has a current ratio of 13.47, a quick ratio of 13.47 and a debt-to-equity ratio of 0.17. The stock has a market cap of $1.10 billion, a PE ratio of -9.27 and a beta of 0.29. The business's 50-day moving average price is $5.65 and its 200-day moving average price is $5.49.

Savara (NASDAQ:SVRA - Get Free Report) last announced its earnings results on Tuesday, August 11th. The company reported ($0.16) earnings per share for the quarter, missing the consensus estimate of ($0.14) by ($0.02). As a group, equities research analysts expect that Savara Inc. will post -0.57 earnings per share for the current fiscal year.

Institutional Trading of Savara

Hedge funds and other institutional investors have recently made changes to their positions in the business. Prudential Financial Inc. acquired a new stake in Savara in the 2nd quarter valued at $30,000. BNP Paribas Financial Markets raised its stake in Savara by 52.3% in the 2nd quarter. BNP Paribas Financial Markets now owns 13,473 shares of the company's stock valued at $31,000 after purchasing an additional 4,626 shares during the last quarter. Brevan Howard Capital Management LP acquired a new position in Savara in the 2nd quarter valued at $33,000. Russell Investments Group Ltd. lifted its holdings in Savara by 930.5% in the 3rd quarter. Russell Investments Group Ltd. now owns 10,480 shares of the company's stock valued at $37,000 after purchasing an additional 9,463 shares in the last quarter. Finally, CIBC Bancorp USA Inc. purchased a new position in Savara in the 3rd quarter valued at $44,000. Institutional investors and hedge funds own 87.93% of the company's stock.

Savara Company Profile

Savara Inc NASDAQ: SVRA is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare respiratory diseases. The company specializes in in-licensing, advancing and potentially bringing to market novel treatments that address severe pulmonary conditions with high unmet medical need.

The company's lead candidate, Molgradex (recombinant human granulocyte-macrophage colony-stimulating factor, or GM-CSF), is under regulatory review for the treatment of autoimmune pulmonary alveolar proteinosis (PAP), a rare lung disease characterized by the accumulation of surfactant.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source